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Translational Relevance (136 of 150 words) 
Patients with advanced cancer and bone metastases often have elevated levels of the 
bone turnover markers urinary N-telopeptide (uNTx) and serum bone-specific alkaline 
phosphatase (sBSAP). Bone antiresorptive agents such as denosumab and zoledronic 
acid can reduce uNTx and sBSAP levels. Our study demonstrated that uNTx and 
s%6$3OHYHOVPHGLDQOHYHOVFRPSDUHGZLWKPHGLDQOHYHOV after 3 months of 
treatment with denosumab or zoledronic acid were associated with reduced overall 
survival and increased risk of disease progression and disease progression in bone. 
These results suggest a potential utility for uNTx and sBSAP as easily measurable, 
noninvasive, early predictors for response and survival in patients with advanced cancer 
and bone metastases who are receiving bone antiresorptive agents. Evaluating uNTx 
and sBSAP levels could complement established prognostic markers based on disease 
stage factors. 
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Abstract (250 of 250 words) 
Purpose: Bone antiresorptive agents can significantly reduce bone turnover markers 
(BTMs) in patients with advanced cancer. We evaluated association of changes in 
BTMs with overall survival (OS), disease progression (DP), and disease progression in 
bone (DPB) in patients with advanced cancer and bone metastases following 
denosumab or zoledronic acid treatment.  
Experimental Design: This is an integrated analysis of patient-level data from three 
identically designed, blinded, phase III trials with patients randomized to subcutaneous 
denosumab or intravenous zoledronic acid. Levels of the BTMs urinary N-telopeptide 
(uNTx) and serum bone-specific alkaline phosphatase (sBSAP) measured at study 
entry and month 3 were analyzed. OS, DP, and DPB were compared in patients with 
BTMs  median vs < median based on month 3 assessments. 
Results: uNTx levels the median of 10.0 nmol/mmol at month 3 were associated with 
significantly reduced OS compared with levels < median (HR for death 1.85, P<0.0001). 
sBSAP levels PHGLDQRI6 ng/mL were associated with significantly reduced OS 
compared with levels < median (HR 2.44, P<0.0001). uNTx and sBSAP levels  median 
at month 3 were associated with significantly greater risk of DP (HR 1.31, P<0.0001 and 
HR 1.71, P<0.0001, respectively) and DPB (HR 1.11, P=0.0407 and HR 1.27, 
P<0.0001, respectively). 
Conclusions: BTM levels PHGLDQDIWHU 3 months of bone antiresorptive treatment 
were associated with reduced OS and increased risk of DP and DPB. Assessment of 
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uNTx and sBSAP levels after bone antiresorptive therapy may add to identification of 
patients at risk for worse clinical outcomes. 
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Introduction 
Bone is a frequent and often the only site of metastasis in patients with advanced solid 
tumors such as breast cancer, prostate cancer, or lung cancer (1-7), and bone 
metastases are often associated with significant morbidity and poor prognosis (3, 6, 8). 
Metastatic bone disease disrupts the homeostasis of osteoclast-mediated bone 
resorption and osteoblast-mediated bone formation, leading to dysregulation of normal 
bone remodeling processes (2, 3).  
The loss of bone homeostasis compromises the structural integrity of the 
skeleton and leads to clinical complications including pathological fractures, spinal cord 
compression, life-threatening hypercalcemia, or the need for radiation or surgery to 
bone to prevent or treat fractures (2, 5, 8-10). These clinical complications, collectively 
termed skeletal-related events (SREs) (8, 11-13), often lead to severe pain and a 
significant decrease in quality of life (14-17). 
Osteoblasts produce the cytokine receptor activator of nuclear factor kappa-B 
ligand (RANKL), which is an essential mediator of osteoclast function, formation, and 
survival (6, 18, 19). The presence of tumor cells in the bone stimulates osteoblasts to 
increase RANKL expression (6, 18, 19), which in turn induces osteoclast-mediated bone 
resorption and bone destruction, leading to SREs (20, 21). 
Bone antiresorptive agents such as denosumab and zoledronic acid inhibit 
osteoclast activity (22-27) and are approved for the prevention of SREs in patients with 
bone metastases from solid tumors (28, 29). Denosumab has previously been sho
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be more efficacious than zoledronic acid in preventing SREs in this patient population 
(25-27). 
Patients with advanced cancer and bone metastases typically have elevated 
levels of the bone turnover markers (BTMs) urinary N-telopeptide (uNTx), an indicator of 
osteoclast activity, and serum bone-specific alkaline phosphatase (sBSAP), an indicator 
of osteoblast activity (6, 7, 30-32). Both denosumab and zoledronic acid have been 
shown to significantly reduce uNTx and sBSAP levels (33, 34), and these two BTMs 
have been investigated as potential prognostic factors for monitoring patients with 
cancer who are receiving bone antiresorptive agents. A recent study in 1,901 men with 
castration-resistant prostate cancer demonstrated that decreased baseline levels of 
uNTx and sBSAP were associated with improved overall survival (OS) (35). 
In this retrospective analysis, we used a large integrated dataset from patients 
who had various advanced solid tumors and bone metastases and had received either 
denosumab or zoledronic acid to further explore the relationship between changes in 
BTM (uNTx and sBSAP) levels and clinical outcomes. Here we report the association of 
changes in uNTx and sBSAP levels with OS, disease progression (DP), and disease 
progression in the bone (DPB). 
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Materials and Methods 
Patients and Treatments 
Details of the three identically designed, blinded, phase III trials comparing denosumab 
and zoledronic acid in patients with breast cancer (ClinicalTrials.gov: NCT00321464) 
(27), prostate cancer (ClinicalTrials.gov: NCT00321620) (25), or solid tumors (excluding 
breast cancer and prostate cancer) or myeloma (ClinicalTrials.gov: NCT00330759) (26) 
have been previously reported. In those three parent studies, eligible patients 18 years 
old had received either a SC injection of denosumab 120 mg (XGEVA® Amgen Inc., 
Thousand Oaks, CA, USA) (29) and an IV infusion of placebo every 4 weeks or an IV 
infusion of zoledronic acid 4 mg (Zometa®, Novartis, East Hanover, NJ, USA) (28) and 
an SC injection of placebo every 4 weeks (see Supplementary Fig. S1 for study design). 
In the three parent studies, cUHDWLQLQHFOHDUDQFHP/PLQDQGDQEastern 
Cooperative Oncology Group (ECOG) performance status of ZHUHUHTXLUHGDWVWXG\
entry. Daily supplementation with FDOFLXPPJDQGYLWDPLQ'400 U) was 
strongly recommended. Exclusion criteria included prior treatment with IV 
bisphosphonates, planned radiation or surgery to bone, or unhealed dental or oral 
surgery. 
Patients who participated in the studies had provided written, informed consent 
before any study-specific procedure was performed, except for three patients in the 
zoledronic acid group of the breast cancer study (27), who were excluded from analysis 
due to lack of proper documentation of informed consent. Study protocols were 
approved by the relevant institutional review boards and independent ethics committees 
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for each site, and the studies were conducted in accordance with International 
Conference on Harmonisation guidelines on Good Clinical Practice and the principles of 
the Declaration of Helsinki. 
Assessments of Outcomes 
Levels of uNTx and sBSAP measured at baseline and after 3 months of treatment with 
either denosumab or zoledronic acid were analyzed. Urine was collected from the 
second void of the day, before noon.  uNTx measurements (corrected for urine 
creatinine levels) were performed by Amgen Inc. (Thousand Oaks, CA, USA) or PPD 
Development (Richmond, VA, USA) using an enzyme-linked immunosorbent assay 
(ELISA; Osteomark, Seattle, WA, USA). sBSAP measurements were performed by the 
University of Liege (Liege, Belgium) using a chemiluminescent assay (Access Ostase 
reagents on the Access immunoassay system, Beckman Coulter, Brea, CA, USA). OS, 
DP, and DPB were compared in patients who had uNTx and sBSAP levels  or < the 
median levels at month 3. The time point of 3 months after antiresorptive treatment was 
selected to provide adequate time for response to therapy. 
Statistical Analysis 
The integrated patient-level dataset from patients with solid tumors enrolled in the three 
phase III trials (25-27) was used for this analysis. This excludes the multiple myeloma 
patient population enrolled in the solid tumor and myeloma study (26). In this post-hoc 
analysis on uNTx and sBSAP levels, respectively, Cox models were used to analyze the 
DVVRFLDWLRQEHWZHHQWKHOHYHORU the median levels) at month 3 and OS, DP, and 
DPB by taking the level category as the independent variable and stratified by study, 
treatment, and the actual stratification factors based on month 3 assessments. To 
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determine the impact of risk factors associated with a more advanced disease state, 
additional analyses that included the covariates of baseline visceral metastases 
(presence vs absence), baseline number of bone metastases (2 vs >2), or baseline 
ECOG performance status category  (0±1 YV2) were performed.  
For uNTx and sBSAP, the absolute value of levels at month 3 and percent 
change from baseline were determined. OS, DP, and DPB were analyzed by month 3 
BTM category RU median) as well as by percent change FDWHJRU\RU median 
percent change). In additLRQFOLQLFDORXWFRPHVZHUHDQDO\]HGE\SDWLHQWV¶ combined 
category of uNTx and sBSAP levels at month 3: HL (high-low: uNTx  median and 
sBSAP < median at month 3), LH (low-high: uNTx < median and sBSAP  median at 
month 3), LL (low-low: uNTx < median and sBSAP < median at month 3), and HH (high-
high: uNTx  PHGLDQDQG sBSAP median at month 3). 
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Results 
Patients 
A total of 5,543 patients with advanced solid tumors and bone metastases from the 
three parent phase III studies (25-27) were included in this integrated analysis 
(denosumab, n = 2,775; zoledronic acid, n = 2,768). The myeloma patient population 
(n = 180) from the solid tumor and myeloma study (26) was excluded from this analysis. 
Data on BTM levels were available for most of the patients: uNTx, n = 4,299 (breast 
cancer, n = 1,705; prostate cancer, n = 1,527; and NSCLC, n = 461) and sBSAP, 
n = 4,316 (breast cancer, n = 1,708; prostate cancer, n = 1,512; and NSCLC, n = 480). 
Patient demographics and baseline clinical characteristics were generally 
balanced between the treatment groups (Table 1). Both groups had a median age of 
63.0 years. Most (90.0%) patients had an ECOG performance status of 0±1. A total of 
2,337 (42.2%) patients had visceral metastases, 4,185 (75.5%) had up to 2 metastatic 
lesions in the bone. Median levels of uNTx and sBSAP at baseline were 
43.7 nmol/mmol and 21.1 ng/mL, respectively. 
Changes in BTM Levels at Month 3 of Bone Antiresorptive Treatment 
After 3 months of treatment with either denosumab or zoledronic acid, median levels of 
uNTx for all patients decreased from 43.7 nmol/mmol to 10.0 nmol/mmol 
(Supplementary Table S1). This decrease was consistent across tumor types, with 
month 3 median levels of 10.4 nmol/mmol for patients with breast cancer and 
9.6 nmol/mmol for patients with prostate cancer or non-small cell lung cancer (NSCLC). 
Median levels of sBSAP decreased from 21.1 ng/mL to 12.6 ng/mL for all patients 
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(Supplementary Table S1). By tumor type, median levels of sBSAP at month 3 were 
higher in patients with prostate cancer (21.4 ng/mL) than in patients with breast cancer 
or NSCLC (10.9 ng/mL and 10.1 ng/mL, respectively). 
Association of BTM Levels With OS, DP, and DPB at Month 3 of Bone 
Antiresorptive Treatment 
In the integrated analysis, pDWLHQWVZLWKX17[OHYHOVPHGLDQDWPRQWKKDG
significantly reduced OS compared with patients with uNTx levels < median (HR 1.85, 
95% confidence interval (CI): 1.67±2.04; P < 0.0001) (Fig, 1A; Table 2). Similarly, 
patients with sBSAP lHYHOV median at month 3 had significantly reduced OS compared 
with those who had sBSAP levels < median (HR 2.44, 95% CI: 2.20±2.71; P < 0.0001) 
(Fig 1B; Table 2). 
The risk of DP significantly increased for patients with uNTx and sBSAP levels 
 median at month 3 (HR 1.31, 95% CI: 1.21±1.41; P < 0.0001 and HR 1.71, 95% CI: 
1.57±1.85; P < 0.0001, respectively) (Fig 2A and B; Table 2). Similarly, the risk of DPB 
significantly increased for patients with uNTx and sBSAP levels  median at month 3 
(HR 1.11, 95% CI: 1.01±1.24; P = 0.0407 and HR 1.27, 95% CI: 1.14±1.41; P < 0.0001, 
respectively) (Fig 3A and B; Table 2). 
Clinical outcomes were also assessed by tumor type. In patients with breast 
cancer, uNTx and sBSAP levels  median at month 3 were associated with significantly 
reduced OS and a significantly increased risk of DP and DPB (Table 2), consistent with 
results seen for the combined patient population. In patients with prostate cancer, uNTx 
and sBSAP levels  median at month 3 were associated with a significantly reduced OS 
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and significantly increased risk of DP; however, nonsignificant changes in the risk of 
'3%ZHUHVHHQZLWKOHYHOV median at month 3 for uNTx (HR 0.86, 95% CI: 0.73±1.02; 
P = 0.0911) and for sBSAP (HR 1.07, 95% CI: 0.90±1.27; P = 0.4234) compared with 
those with levels < median (Table 2). In patients with NSCLC, uNTx and sBSAP levels 
 median at month 3 were associated with significantly reduced OS and significantly 
increased risk of DP. In addition, sBSAP levels  median at month 3 were associated 
with a significantly increased risk of DPB. Although uNTx OHYHOV median at month 3 
showed an association with increased risk of DPB, this association did not reach 
statistical significance (HR 1.41, 95% CI: 0.97±2.03; P = 0.0691). 
OS, DP, and DPB Adjusted for Baseline Visceral Metastases, Bone Metastases, or 
ECOG Performance Status Category 
Significant associations of uNTx and sBSAP levels with OS, DP, and DPB were 
observed even after adjusting for factors associated with advanced cancer such as 
baseline visceral metastases, baseline multiple metastatic bone lesions, and baseline 
ECOG performance status category (Supplementary Table S2). After adjusting for 
baseline visceral metastases, uNTx levels  median, compared with uNTx levels 
< median, were associated with reduced OS (HR 1.81, 95% CI: 1.64±2.00; P < 0.0001), 
greater risk of DP (HR 1.29, 95% CI: 1.19±1.39; P < 0.0001), and also greater risk of 
DPB (HR 1.11, 95% CI: 1.00±1.23; P = 0.0469). Similarly, sBSAP levels  median, 
compared with sBSAP levels < median, were associated with reduced OS (HR 2.41, 
95% CI: 2.17±2.68; P < 0.0001), greater risk of DP (HR 1.69, 95% CI: 1.56±1.83; 
P < 0.0001), and also greater risk of DPB (HR 1.26, 95% CI: 1.14±1.41; P < 0.0001). 
Similar results were observed after adjusting for baseline multiple metastatic bone 
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lesions and baseline ECOG performance status category; i.e., month 3 BTM levels 
 median, compared with BTM levels < median, were associated with significantly 
reduced OS and a significantly increased risk of DP and DPB (Supplementary Table 
S2). 
2XWFRPHVE\&DWHJRU\RU0HGLDQRI0RQWK%703HUFHQW&KDQJH)URP
Baseline  
Overall, sBSAP level is reduced from baseline to month 3, with the median percent 
change in sBSAP from baseline to month 3 of ±35.6%. Patients who achieved a smaller 
reduction from baseline in sBSAP levels (i.e., percent change from baseline  
 ±35.6%) had reduced OS and an increased risk of DP and DPB. On the other hand, 
patients who achieved further reduction in sBSAP levels (i.e., percent change from 
baseline < ±35.6%) had improved OS and decreased risk of DP and DPB 
(Supplementary Fig. 2A-C). An association of outcomes and percentage change in 
uNTx levels was not observed (data not shown). 
Outcomes by uNTx and sBSAP Combined &DWHJRU\RU0HGLDQDW0RQWK 
Assessment RISDWLHQWV¶PRQWKFRPELQHGX1Tx and sBSAP levels demonstrated 
reduced OS for the HH group (uNTx and sBSAP both  median at month 3) and LH 
group (uNTx < median and sBSAP  median at month 3) compared to the HL (uNTx 
 median and sBSAP < median at month 3) and LL groups (uNTx and sBSAP both 
< median at month 3) (Fig. 4A). The risk of DP increased in the HH and LH groups 
compared to the LL and HL groups (Fig. 4B). A similar trend, though less pronounced, 
was also observed for DPB (Fig. 4C). 
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Discussion 
In this retrospective study, we analyzed patient-level data from a total of 5,543 patients 
with advanced solid tumors and bone metastases who had participated in three 
identically designed phase III trials and had received the bone antiresorptive agents 
denosumab or zoledronic acid. Overall, our analysis demonstrated that  median levels 
of the BTMs uNTx and sBSAP after 3 months of bone antiresorptive treatment were 
associated with significantly reduced OS and significantly increased risk of DP and 
DPB.  
Across tumor types (breast cancer, prostate cancer, and NSCLC), month 3 uNTx 
and sBSAP OHYHOV median were associated with significantly reduced OS and a 
significantly increased risk of DP, consistent with data observed for all tumor types 
combined. +RZHYHUWKHSDWWHUQRIDVVRFLDWLRQRI%70OHYHOV median with DPB 
appeared to vary by tumor type. Month 3 levels of both uNTx and s%6$3 median 
were associated with a significantly increased risk of DPB in patients with breast cancer 
but were not associated with an increased risk of DPB in patients with prostate cancer. 
In patients with NSCLC, month 3 s%6$3OHYHOV median were associated with a 
significant increase in the risk of DPB, whereas month X17[OHYHOV median were 
associated with a nonsignificant increase in the risk of DPB. 
Of interest, our study demonstrated an association between clinical outcomes 
and serum sBSAP percentage change. Patients who achieved a smaller reduction from 
baseline in sBSAP levels had reduced OS and increased risk of DP and DPB 
(Supplementary Fig 2A-C). Additional studies and analyses (especially multivariate 
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analyses that include multiple covariates) are required to further evaluate the correlation 
of percent changes from baseline in levels of sBSAP and/or uNTx with clinical 
outcomes. 
In a separate analysis, we observed a significant association between clinical 
outcomes and BTM levels when patients were categorized into HL, LH, LL, and HH 
subgroups according to their combined uNTx and sBSAP levels at month 3 (Fig. 4 A±
C). Patients with high levels of both uNTx and sBSAP at month 3  median levels) had 
substantially reduced OS and an increased risk of DP and, to a lesser extent, an 
increased risk of DPB. A similar negative correlation, was also observed in patients with 
high sBSAP PHGLDQOHYHOEXWORZX17[ (< median level) at month 3. 
Previous studies have shown the potential prognostic value of uNTx and sBSAP 
levels in patients with solid tumors and bone metastases. A recent study in patients with 
prostate cancer showed low baseline uNTx and sBSAP levels to be prognostic and to 
be associated with longer OS (35). Low uNTx and sBSAP levels were also shown to be 
associated with positive clinical outcomes in patients with bone metastases secondary 
to prostate cancer, NSCLC, or other solid tumors (20, 21, 36, 37), independent of 
whether patients had received bone antiresorptive agents. Similar to findings from our 
current study, Coleman et al 2005 (20) reported significantly reduced OS and 
significantly increased risk of DPB in patients with persistently high uNTx levels 
 nmol/mmol creatinine) to moderate uNTx levels (50 to 99 nmol/mmol creatine) vs 
patients with low uNTx levels (<50 nmol/mol creatinine). Also, that study reported 
significantly reduced OS and significantly increased risk of DPB in patients with 
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persistently high serum sBSAP levels 8/ vs patients with low sBASP levels 
(<146 U/L).  
Historically, sBSAP has been known to be a potential prognostic marker in bone 
metastases that are secondary to advanced cancer, whereas uNTx is an emerging 
marker (20, 38-40). However, to date, neither has been shown to be a definitive 
prognostic marker in this patient population. As such, an approach that includes 
assessing levels of both uNTx and sBSAP might provide additional information 
regarding potential clinical outcomes in patients with advanced cancer and bone 
metastases. 
Tumor growth in the bone is typically associated with increased rates of bone 
resorption and formation that might be reflected by increased levels of the biochemical 
markers of bone metabolism such as uNTx and sBSAP (20, 21). Therefore, modalities 
that reduce bone turnover rates might impact tumor growth and thus limiting DPB and 
improving survival (20, 21). Denosumab and zoledronic acid are potent bone 
antiresorptive agents that have been shown to significantly reduce the levels of BTMs 
such as uNTx and sBSAP (33, 34). As such, decreased levels of uNTx and sBSAP after 
treatment with denosumab or zoledronic might be an indicator of reduced tumor growth 
in the bone due to reduced bone turnover rates, whereas high levels of these BTMs 
might indicate continued tumor growth. However, data from our study do not address 
the reason for the observed associations between uNTx or s%6$3OHYHOV median at 
month 3 of antiresorptive therapy and worse clinical outcomes. Possible explanations 
for this observed association include the possibility that patients responding to therapy 
targeted at their primary tumors may have lower uNTx and sBSAP levels than those not 
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responding to therapy, the possibility of involvement of bone antiresorptive agents, or 
reasons unrelated to the primary tumor or bone antiresorptive agents. 
Other baseline variables shown to be associated with improved OS, mostly in 
patients with prostate cancer, include low alkaline phosphatase levels (35, 40, 41), 
absence of prior SREs (35, 42, 43), absence of visceral metastases (35, 40, 44), better 
ECOG performance status (35, 37, 40), low levels of prostate-specific antigen (PSA) 
(35, 40), and high hemoglobin levels (35, 37, 40, 44). Monitoring PSA levels is limited to 
the prostate cancer setting, and even within this setting, challenges have been 
encountered with accurate interpretation of PSA levels following treatment with new 
therapies that may have novel mechanisms of action. As an example, sipuleucel-T was 
reported to improve survival with no impact on early PSA levels (45). In other cases, 
PSA values have been shown to first rise and then decline following effective systemic 
treatment, thus making timing of sampling an important factor (45, 46). As such, 
additional variables are needed for predicting clinical outcomes, especially markers that 
show prognostic value across tumor types.  
Several limitations of our study must be noted. This study analyzed data from 
patients originally recruited for clinical trials in which individuals with poor performance 
(ECOG performance status >2) or serious medical illnesses were excluded from 
enrollment, thereby limiting the generalizability of our findings to real world settings. In 
our study, we defined high uNTx or sBSAP as PHGLDQDWPRQWKRIDQWLUHVRUSWLYH
therapy, and these levels were used as cutoffs to determine association with clinical 
outcomes. However, these cutoff levels may not necessarily reflect definitive 
categorizations for these biochemical markers, and it is possible that different results 
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could be obtained by choosing different cutoff levels. In addition, the three parent phase 
III studies were not prospectively designed to collect all potential covariates for OS, DP, 
and DPB as the objective of the original studies was to evaluate risk reduction for time 
to first SRE between denosumab and zoledronic acid.  Another limitation is tumor 
heterogeneity in the analyzed patient population. 
While the results of this study do not establish a causal link between decreased 
levels of sBSAP and uNTx and clinical outcomes, they suggest a potential utility for 
these BTMs as easily measurable, noninvasive, early predictors for response and 
survival in patients with advanced cancer and bone metastases who are receiving bone 
antiresorptive agents such as denosumab or zoledronic acid. In this patient population, 
changes in BTM levels to higher than or lower than levels at baseline might provide 
insights into potential clinical outcomes. Taken together, our findings and the findings 
from earlier studies appear to point to the gross prognostic value of serum sBSAP and 
uNTx levels, either at baseline or after treatment with bone antiresorptive agents.  
In conclusion, pDWLHQWVZLWK%70OHYHOVPHGLDQDWPRQWKRIDQWLUHVRUSWLYH
therapy had significantly worse clinical outcomes including OS, DP, and DPB than 
patients whose BTM levels were < median. Therefore, assessment of BTM levels after 
antiresorptive therapy may add to the identification of patients most at risk for 
decreased OS and increased DP and DPB in this patient population. 
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 Table 1. Baseline demographic and clinical characteristicsa 
 Characteristic 
Denosumab  
120 mg Q4W 
(n = 2,775) 
Zoledronic acid  
4 mg Q4W 
(n = 2,768) 
All  
(N = 5,543) 
Sex, n (%) 
   
Female 1,286 (46.3) 1,310 (47.3) 2,596 (46.8) 
Male 1,489 (53.7) 1,458 (52.7) 2,947 (53.2) 
Median age (IQR), years 63.0 (54.0±71.0) 63.0 (54.0±72.0) 63.0 (54.0±71.0) 
Race, n (%) 
   
White 2,352 (84.8) 2,320 (83.8) 4,672 (84.3) 
ECOG PS, n (%) 
   
0±1 2,514 (90.6) 2,472 (89.3) 4,986 (90.0) 
 258 (9.3) 288 (10.4) 546 (9.9) 
Missing 3 (0.1) 8 (0.3) 11 (0.2) 
Primary tumor type, n (%) 
   
Breast cancer 1,026 (37.0) 1,020 (36.8) 2,046 (36.9) 
Prostate cancer 950 (34.2) 951 (34.4) 1,901 (34.3) 
Non-small cell lung 
cancer 
350 (12.6) 352 (12.7) 702 (12.7) 
Other 449 (16.2) 445 (16.1) 894 (16.1) 
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Median time from 
diagnosis of cancer to 
randomization (IQR), 
months 
26.45 (8.18±
66.10) 
27.04 (8.44±68.07) 26.73 (8.31±67.09) 
Median time from 
diagnosis of bone 
metastases to 
randomization (IQR), 
months 
2.22 (1.02±7.20) 2.30 (1.05±7.75) 2.27 (1.02±7.41) 
Presence of visceral 
metastases, n (%) 
1,185 (42.7) 1,152 (41.6) 2,337 (42.2) 
Number of metastatic 
lesions in bone, n (%) 
   
 2,101 (75.7) 2,084 (75.3) 4,185 (75.5) 
>2 674 (24.3) 684 (24.7) 1,358 (24.5) 
Bone turnover markers, 
median (IQR) 
   
uNTx (nmol/mmol) 44.2 (24.8±82.9) 43.5 (25.1±81.8) 43.7 (25.0±82.4) 
sBSAP (ng/mL) 21.1 (14.0±41.5) 21.1 (13.6±41.1) 21.1 (13.8±41.3) 
aExcludes the myeloma patient population. 
ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile 
range; Q4W, every 4 weeks. 
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Table 2. Covariate analysis of OS, DP, and DPB at month 3, overall and by tumor type 
Clinical Outcome na Hazard ratio (95% CI) P value 
All tumor typesb     
uNTx 4,299d   
OSc  1.85 (1.67±2.04) <0.0001 
DP  1.31 (1.21±1.41) <0.0001 
DPB  1.11 (1.01±1.24) 0.0407 
sBSAP 4,316e   
OSc  2.44 (2.20±2.71) <0.0001 
DP  1.71 (1.57±1.85) <0.0001 
DPB  1.27 (1.14±1.41) <0.0001 
Breast cancer     
uNTx 1,705f   
OSc  1.54 (1.27±1.87) <0.0001 
DP  1.21 (1.07±1.38) 0.0024 
DPB  1.23 (1.05±1.44) 0.0087 
sBSAP 1,708g   
OSc  2.97 (2.42±3.63) <0.0001 
DP  1.67 (1.47±1.89) <0.0001 
DPB  1.56 (1.34±1.82) <0.0001 
Prostate cancer     
uNTx 1,527h   
OSc  2.12 (1.82±2.48) <0.0001 
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DP  1.32 (1.17±1.50) <0.0001 
DPB  0.86 (0.73±1.02) 0.0911 
sBSAP 1,512i   
OSc  2.81 (2.39±3.32) <0.0001 
DP  1.83 (1.61±2.09) <0.0001 
DPB  1.07 (0.90±1.27) 0.4234 
Non-small cell lung cancer    
uNTx 461j   
OSc  1.83 (1.44±2.33) <0.0001 
DP  1.30 (1.03±1.63) 0.0249 
DPB  1.41 (0.97±2.03) 0.0691 
sBSAP 480k   
OSc  1.66 (1.31±2.12) <0.0001 
DP  1.37 (1.09±1.71) 0.0061 
DPB  1.55 (1.09±2.21) 0.0152 
aNumber of patients included in the analysis. 
bExcludes the myeloma patient population. 
cOS is measured by death of all cause. An HR >1 indicates an increased risk of death 
and decreased OS. 
dn = 2,IRUSDWLHQWVZLWKX17[OHYHOVPHGLDQDQGn = 2,149 for patients with uNTx 
levels < median. 
en = 2,157 for patients with s%6$3OHYHOVPHGLDQDQGn = 2,159 for patients with 
sBSAP levels < median. 
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fn  IRUSDWLHQWVZLWKX17[OHYHOVPHGLDQDQGn = 810 for patients with uNTx 
levels < median. 
gn = 855 for patients with s%6$3OHYHOVPHGLDQDQGn = 853 for patients with sBSAP 
levels < median. 
hn = 764 for patients with uNTx OHYHOVPHGLDQDQGn = 763 for patients with uNTx 
levels < median. 
in = 758 for patients with s%6$3OHYHOVPHGLDQDQGn = 754 for patients with sBSAP 
levels < median. 
jn = 231 IRUSDWLHQWVZLWKX17[OHYHOVPHGLDQDQGn = 230 for patients with uNTx 
levels < median. 
kn = 239 for patients with s%6$3OHYHOVPHGLDQDQGn = 241 for patients with sBSAP 
levels < median. 
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Figure Legends 
 
Fig 1. OS stratified by uNTx (A) and sBSAP (B) levels at month 3.a 
aExcludes the myeloma patient population. 
 
Fig 2. DP stratified by uNTx (A) and sBSAP (B) levels at month 3.a 
aExcludes the myeloma patient population.  
 
Fig 3. DPB stratified by uNTx (A) and sBSAP (B) levels at month 3.a 
aExcludes the myeloma patient population.  
 
Fig 4. OS (A), DP (B), and DPB (C) stratified by uNTx and sBSAP combined category 
 or < median) at month 3a,b 
aExcludes the myeloma patient population. 
bCombined category of uNTx and sBSAP levels at month 3: HL (high-low: NTX 
 median and sBSAP < median at month 3), LH (low-high: uNTx < median and sBSAP 
PHGLDQDWPRQWK//ORZ-low: uNTx < median and sBSAP < median at month 3), 
and HH (high-KLJKX17[PHGLDQDQGsBSAP median at month 3). 
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Figures 
Fig 1. OS stratified by uNTx (A) and sBSAP (B) levels at month 3a 
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Fig 2. DP stratified by uNTx (A) and sBSAP (B) levels at month 3a 
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Fig 3. DPB stratified by uNTx (A) and sBSAP (B) levels at month 3a 
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Fig 4. OS (A), DP (B), and DPB (C) stratified by uNTx and sBSAP combined 
FDWHJRU\ or < median) at month 3a,b 
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Supplementary Material (Online Only) 
 
Legend to Supplementary Figure S1. Combined patient population from the three 
phase III studies and treatments (25-27). 
aIV product dose adjusted for baseline creatinine clearance and subsequent dose 
intervals determined by serum creatinine, per prescribing information for zoledronic acid 
(28). 
Q4W, every 4 weeks 
 
Legend to Supplementary Figure S2. OS (A), DP (B), and DPB (C) stratified by 
FDWHJRU\RU< median) of month 3 sBSAP percent change from baseline.a 
aExcludes the myeloma patient population. 
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Supplementary Fig S1. Combined patient population from the three phase III studies 
and treatments (25-27). 
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Supplementary Table S1. BTM levels at baseline and at month 3 after bone 
antiresorptive treatment 
 Median BTM levels 
 At baseline At month 3 
Tumor type na Median (IQR) nb Median (IQR) 
uNTx (nmol/mmol)     
All tumor typesc 4,951 43.7 (25.0±82.4) 4,299 10.0 (6.3±19.9) 
Breast cancer  1,797 42.6 (24.9±74.6) 1,705 10.4 (6.6±20.8) 
Prostate cancer  1,802 51.9 (27.9±112.0) 1,527 9.6 (6.0±20.8) 
Non-small cell 
lung cancer  
583 36.6 (21.4±65.1) 461 9.6 (5.5±17.7) 
sBSAP (ng/mL)     
All tumor typesc 5,080 21.1 (13.8±41.3) 4,316 12.6 (8.7±25.5) 
Breast cancer 1,814 20.0 (13.9±30.9) 1,708 10.9 (8.3±17.5) 
Prostate cancer  1,846 32.9 (17.4±86.5) 1,512 21.4 (10.8±69.0) 
Non-small cell 
lung cancer 
622 15.0 (11.1±23.7) 484 10.1 (7.7±15.4) 
aNumber of patients with uNTx or sBSAP measurement at baseline. 
bNumber of patients with uNTx or sBSAP measurement at month 3. 
cExcludes the myeloma patient population. 
IQR, interquartile range. 
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Supplementary Table S2. Covariate analysis of OS, DP, and DPB at month 3 adjusted 
for baseline visceral metastases, bone metastases, or ECOG categorya 
Clinical outcomes nb Hazard ratio (95% CI) P value 
Baseline visceral metastasis 
(presence vs absence)    
uNTx  4,299d   
OSc  1.81 (1.64±2.00) <0.0001 
DP  1.29 (1.19±1.39) <0.0001 
DPB  1.11 (1.00±1.23) 0.0469 
sBSAP 4,316e   
OS c  2.41 (2.17±2.68) <0.0001 
DP  1.69 (1.56±1.83) <0.0001 
DPB  1.26 (1.14±1.41) <0.0001 
Baseline number of bone 
metastases YV!    
uNTx  4,299d   
OSc  1.83 (1.66±2.02) <0.0001 
DP  1.30 (1.20±1.40) <0.0001 
DPB  1.14 (1.03±1.27) 0.0105 
sBSAP 4,316e   
OSc  2.44 (2.20±2.72) <0.0001 
DP  1.72 (1.58±1.86) <0.0001 
DPB  1.38 (1.24±1.54) <0.0001 
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Baseline ECOG PS category 
(0±YV    
uNTx 4,299d   
OSc  1.80 (1.63±1.99) <0.0001 
DP  1.29 (1.19±1.39) <0.0001 
DPB  1.11 (1.00±1.24) 0.0415 
sBSAP 4,316e   
OSc  2.39 (2.16±2.66) <0.0001 
DP  1.69 (1.56±1.83) <0.0001 
DPB  1.27 (1.14±1.41) <0.0001 
aExcludes the myeloma patient population. 
bNumber of patients included in the analysis. 
cOS is measured by death of all cause. An HR >1 indicates an increased risk of death 
and decreased OS. 
dn = 2,IRUSDWLHQWVZLWKX17[OHYHOVPHGLDQDQGn = 2,149 for patients with uNTx 
levels < median. 
en = 2,157 for patients with s%6$3OHYHOVPHGLDQDQGn = 2,159 for patients with 
sBSAP levels < median. 
ECOG PS, Eastern Cooperative Oncology Group performance status. 
 
CCR-15-3086 BTM manuscript                Bone turnover markers in patients with advanced cancer  
44 
 
Supplementary Fig S2. OS (A), DP (B), and DPB (C) VWUDWLILHGE\FDWHJRU\RU
< median) of month 3 sBSAP percent change from baseline.a 
  
